Sera Prognostics Targets 2028 Runway as PRIME Study Bolsters Commercial Pivot
Sera Prognostics reported a narrowed annual net loss of $31.9 million for 2025, supported by a robust $95.8 million cash position that extends its operational runway into 2028. Following the successful publication of its PRIME study—which demonstrated a 56% reduction in very preterm births—the company is aggressively shifting its focus toward state-level payer engagement and commercial scaling.